氨溴索联合布地奈德治疗新生儿肺炎的效果

Effect of Ambroxol Combined with Budesonide in the Treatment of Neonatal Pneumonia

目的:探讨氨溴索联合布地奈德治疗新生儿肺炎的有效性及安全性。方法:选取2021年1月—2023年1月在本院就诊的95例新生儿肺炎患者,按照治疗方式不同分为对照组(n=45)和研究组(n=50)。对照组予以常规治疗方案,研究组在常规治疗基础上应用氨溴索+布地奈德治疗。比较两组总有效率、不良反应发生率、血清炎性因子、肺通气功能、动脉血气指标。结果:研究组总有效率高于对照组(P<0.05);研究组与对照组不良反应总发生率比较,差异无统计学意义(P>0.05);研究组FEV1、FEV1/FVC、PaO_(2)高于对照组,PaCO_(2)低于对照组(P<0.05);研究组CRP、PCT、TNF-α水平低于对照组(P<0.05)。结论:布地奈德与氨溴索联合应用可增强新生儿肺炎患儿的病情控制效果,有效减轻患者症状、炎症反应,对患者肺功能、动脉血气状况均可起到良好的改善作用,且不良反应少,安全性良好。

Objective:To investigate the efficacy and safety of ambroxol combined with budesonide in the treatment of neonatal pneumonia.Methods:A total of 95 patients with neonatal pneumonia who were treated in our hospital from January 2021 to January 2023 were selected and divided into control group(n=45)and study group(n=50)according to diferent treatment methods.The control group was given routine treatment,and the study group was treated with ambroxol+budesonide on the basis of routine treatment.The total effective rate,incidence of adverse reactions,serum inflammatory factors,pulmonary ventilation function and arterial blood gas indexes were compared between the two groups.Results:The total effective rate of the study group was higher than that of the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the study group and the control group(P>0.05).FEV1,FEV1/FVC and PaO_(2) in the study group were higher than those in the control group,while PaCO_(2) was lower than that in the control group(P<0.05).The levels of CRP,PCT and TNF-α in the study group were lower than those in the control group(P<0.05).Conclusion:The combined application of budesonide and ambroxol can enhance the disease control effect of neonatal pneumonia children,effectively reduce the symptoms and inflammatory reactions of patients,and improve the pulmonary function and arterial blood gas status of patients,with few adverse reactions and good safety.